AnaptysBio, Inc. ANAB Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 17.6%+107pp | 20.4%+146pp | -16.9%+241pp | -69.9%+463pp | -89.6%+617pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.3× | 0.6×+0.4× | 0.4×+0.3× | 0.3×+0.3× | 0.3×+0.2× | |
| Liquidity | ||||||
| Current ratio | 7.6×-0.7× | 9.1×-0.4× | 8.7×-1.5× | 8.2×-0.9× | 8.2×-3.3× | |
| Leverage | ||||||
| Debt-to-equity | 0×-0.5× | 0×-0.2× | —— | —— | 0.5×+0.1× | |
| Net debt / EBITDA | -6×— | -4.9×— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $0.44-60.0% | $1.29-48.2% | -$1.01-135% | -$1.55-530% | $1.11-37.7% | |
| Valuation | ||||||
| Market capitalization | $1.59B+180% | $1.34B+233% | $856.53M-15.3% | $685.15M+0.1% | $570.1M-5.4% | |
| Price / sales | 6.9×+1.8× | 5.7×+1.3× | 5.1×-12.6× | 5.6×-16.9× | 5.1×-21.2× | |
| Price / book | 125.1×+108× | 36.1×+30.4× | —— | —— | 16.8×+4.1× | |
| EV / EBITDA | 32.6×— | 22.8×— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do AnaptysBio, Inc.'s ratios come from?
- Every ratio is computed from AnaptysBio, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
